Celularity (NASDAQ:CELU) Posts Quarterly Earnings Results

Celularity (NASDAQ:CELU) released its quarterly earnings results on Tuesday. The company reported $0.02 earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $5.43 million for the quarter.

Celularity Stock Up 8.6%

Shares of CELU traded up $0.10 during trading hours on Tuesday, reaching $1.26. 44,319 shares of the company traded hands, compared to its average volume of 1,337,479. The stock has a market capitalization of $40.89 million, a PE ratio of -0.46 and a beta of 0.77. Celularity has a fifty-two week low of $0.56 and a fifty-two week high of $2.55. The stock has a fifty day simple moving average of $1.30 and a 200 day simple moving average of $1.03.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Celularity stock. C V Starr & Co. Inc. bought a new stake in Celularity, Inc. (NASDAQ:CELU) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity makes up about 0.8% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 4th largest position. C V Starr & Co. Inc. owned about 2.64% of Celularity at the end of the most recent reporting period. Institutional investors own 19.02% of the company’s stock.

Celularity Company Profile

Celularity, Inc is a biotechnology company focused on developing cell therapies and biomaterial products derived from human placental tissue. The company’s platform is designed to use the placenta as a scalable source of allogeneic cells and biomaterials for applications in oncology, immune-mediated diseases, infectious diseases and tissue repair.

Celularity’s development pipeline has included placental-derived natural killer cell programs, including CYNK-001, which has been evaluated for potential use in hematologic cancers and other diseases.